Impact of Testosterone Therapy on Major Cardiovascular Risk in Erectile Dysfunction Patients with Testosterone Deficiency.

IF 2 Q2 UROLOGY & NEPHROLOGY

Research and Reports in Urology Pub Date : 2024-09-17 eCollection Date: 2024-01-01 DOI:10.2147/RRU.S476804

Tanawin Poopuangpairoj, Kun Sirisopana, Chinnakhet Ketsuwan, Wisoot Kongchareonsombat, Yada Phengsalae, Wijittra Matang, Premsant Sangkum

{"title":"Impact of Testosterone Therapy on Major Cardiovascular Risk in Erectile Dysfunction Patients with Testosterone Deficiency.","authors":"Tanawin Poopuangpairoj, Kun Sirisopana, Chinnakhet Ketsuwan, Wisoot Kongchareonsombat, Yada Phengsalae, Wijittra Matang, Premsant Sangkum","doi":"10.2147/RRU.S476804","DOIUrl":null,"url":null,"abstract":"Objective: The objective of this study was to evaluate major adverse cardiovascular events in erectile dysfunction (ED) patients who received testosterone replacement therapy (TRT) compared with those who did not.Materials and methods: From January 2012 to October 2021, we collected the retrospective data of patients with ED at Ramathibodi Hospital. We divided the patients into two groups: those who received TRT (TRT group) and those with normal testosterone levels and therefore not requiring TRT (non-TRT group). The patients' baseline clinicodemographic data were collected. Major adverse cardiovascular events, including cardiovascular death, ST- and non-ST-elevation myocardial infarction, hospitalization from congestive heart failure, transient ischemic attack, and ischemic stroke, were collected and analyzed within 2 years after treatment in all groups.Results: Of the 221 patients, 111 were in the TRT group and 110 were in the non-TRT group. In the non-TRT group, one event each of the following occurred: myocardial infarction, transient ischemic attack, and stroke. In the TRT group, no major cardiovascular event occurred during the 2-year follow-up period. However, no significant difference in major cardiovascular events was noted between the two groups (p = 0.314).Conclusion: TRT in ED patients with testosterone deficiency does not increase adverse cardiovascular events when compared with ED patients with normal testosterone level.","PeriodicalId":21008,"journal":{"name":"Research and Reports in Urology","volume":null,"pages":null},"PeriodicalIF":2.0000,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11416101/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Research and Reports in Urology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/RRU.S476804","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: The objective of this study was to evaluate major adverse cardiovascular events in erectile dysfunction (ED) patients who received testosterone replacement therapy (TRT) compared with those who did not.

Materials and methods: From January 2012 to October 2021, we collected the retrospective data of patients with ED at Ramathibodi Hospital. We divided the patients into two groups: those who received TRT (TRT group) and those with normal testosterone levels and therefore not requiring TRT (non-TRT group). The patients' baseline clinicodemographic data were collected. Major adverse cardiovascular events, including cardiovascular death, ST- and non-ST-elevation myocardial infarction, hospitalization from congestive heart failure, transient ischemic attack, and ischemic stroke, were collected and analyzed within 2 years after treatment in all groups.

Results: Of the 221 patients, 111 were in the TRT group and 110 were in the non-TRT group. In the non-TRT group, one event each of the following occurred: myocardial infarction, transient ischemic attack, and stroke. In the TRT group, no major cardiovascular event occurred during the 2-year follow-up period. However, no significant difference in major cardiovascular events was noted between the two groups (p = 0.314).

Conclusion: TRT in ED patients with testosterone deficiency does not increase adverse cardiovascular events when compared with ED patients with normal testosterone level.

查看原文本刊更多论文

睾酮疗法对缺乏睾酮的勃起功能障碍患者主要心血管风险的影响。

研究目的本研究旨在评估接受睾酮替代疗法（TRT）与未接受睾酮替代疗法的勃起功能障碍（ED）患者的主要心血管不良事件：2012年1月至2021年10月，我们收集了拉玛铁博迪医院ED患者的回顾性数据。我们将患者分为两组：接受睾丸激素替代治疗的患者（睾丸激素替代治疗组）和睾丸激素水平正常因而不需要睾丸激素替代治疗的患者（非睾丸激素替代治疗组）。我们收集了患者的基线临床人口学数据。收集并分析了各组患者治疗后两年内的主要心血管不良事件，包括心血管死亡、ST段和非ST段抬高心肌梗死、充血性心力衰竭住院、短暂性脑缺血发作和缺血性中风：在221名患者中，TRT组有111人，非TRT组有110人。在非 TRT 组中，心肌梗死、短暂性脑缺血发作和中风各发生了一次。TRT 组在两年的随访期间没有发生重大心血管事件。然而，两组在重大心血管事件方面没有明显差异（P = 0.314）：结论：与睾酮水平正常的 ED 患者相比，对睾酮缺乏的 ED 患者进行促睾治疗不会增加不良心血管事件。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Research and Reports in Urology UROLOGY & NEPHROLOGY-

CiteScore

3.40

自引率

0.00%

发文量

审稿时长

16 weeks

期刊介绍： Research and Reports in Urology is an international, peer-reviewed, open access, online journal. Publishing original research, reports, editorials, reviews and commentaries on all aspects of adult and pediatric urology in the clinic and laboratory including the following topics: Pathology, pathophysiology of urological disease Investigation and treatment of urological disease Pharmacology of drugs used for the treatment of urological disease Although the main focus of the journal is to publish research and clinical results in humans; preclinical, animal and in vitro studies will be published where they will shed light on disease processes and potential new therapies. Issues of patient safety and quality of care will also be considered.